Autoantibodies against MHC class I polypeptide-related sequence A are associated with increased risk of concomitant autoimmune diseases in celiac patients

BMC Medicine

Carlos López-Larrea¹  Luís Rodrigo²  Marcos López-Hoyos¹  Carlos Bousoño³  Umberto Volta⁶  Eduardo Arranz⁴  José Ramón Vidal-Castiñeira⁵  Beatriz Suárez-Álvarez⁵  Rebeca Alonso-Arias⁵  Lourdes Mozo⁵  Antonio López-Vázquez⁵ 

[1] Fundación Renal “Iñigo Álvarez de Toledo”, Madrid, Spain;Department of Gastroenterology, Hospital Universitario Central de Asturias, Oviedo, Spain;Department of Paediatrics, Hospital Universitario Central de Asturias, Oviedo, Spain;Mucosal Immunology Laboratory, Department of Paediatrics and Immunology-IBGM, University of Valladolid, Valladolid, Spain;Department of Immunology, Hospital Universitario Central de Asturias, Oviedo 33006, Spain;Department of Gastroenterology and Internal Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

关键词: Type 1 diabetes mellitus;    NKG2D;    MICA;    Celiac disease;    Autoimmune diseases;    Autoantibodies;   

Others  :  854968
DOI  :  10.1186/1741-7015-12-34

 received in 2013-12-16, accepted in 2014-01-23,  发布年份 2014

【 摘 要 】

Background

Overexpression of autologous proteins can lead to the formation of autoantibodies and autoimmune diseases. MHC class I polypeptide-related sequence A (MICA) is highly expressed in the enterocytes of patients with celiac disease, which arises in response to gluten. The aim of this study was to investigate anti-MICA antibody formation in patients with celiac disease and its association with other autoimmune processes.

Methods

We tested serum samples from 383 patients with celiac disease, obtained before they took up a gluten-free diet, 428 patients with diverse autoimmune diseases, and 200 controls for anti-MICA antibodies. All samples were also tested for anti-endomysium and anti-transglutaminase antibodies.

Results

Antibodies against MICA were detected in samples from 41.7% of patients with celiac disease but in only 3.5% of those from controls (P <0.0001) and 8.2% from patients with autoimmune disease (P <0.0001). These antibodies disappeared after the instauration of a gluten-free diet. Anti-MICA antibodies were significantly prevalent in younger patients (P <0.01). Fifty-eight patients with celiac disease (15.1%) presented a concomitant autoimmune disease. Anti-MICA-positive patients had a higher risk of autoimmune disease than MICA antibody-negative patients (P <0.0001; odds ratio = 6.11). The risk was even higher when we also controlled for age (odds ratio = 11.69). Finally, we found that the associated risk of developing additional autoimmune diseases was 16 and 10 times as high in pediatric patients and adults with anti-MICA, respectively, as in those without.

Conclusions

The development of anti-MICA antibodies could be related to a gluten-containing diet, and seems to be involved in the development of autoimmune diseases in patients with celiac disease, especially younger ones.

【 授权许可】

   
2014 López-Vázquez et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Gujral N, Freeman HJ, Thomson AB: Celiac disease: prevalence, diagnosis, pathogenesis and treatment. WJG 2012, 18:6036-6059.
• [2]Ludvigsson JF, Rubio-Tapia A, van Dyke CT, Melton LJ 3rd, Zinsmeister AR, Lahr BD, Murray JA: Increasing incidence of celiac disease in a North American population. Am J Gastroenterol 2013, 108:818-824.
• [3]DePaolo RW, Abadie V, Tang F, Fehlner-Peach H, Hall JA, Wang W, Marietta EV, Kasarda DD, Waldmann TA, Murray JA, Semrad C, Kupfer SS, Belkaid Y, Guandalini S, Jabri B: Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature 2011, 471:220-224.
• [4]Marsh MN: Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity (‘celiac sprue’). Gastroenterology 1992, 102:330-354.
• [5]Londei M, Maiuri L, Quaratino S: A search for the holy grail: non-toxic gluten for celiac patients. Gastroenterology 2005, 129:1111-1113.
• [6]Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D: Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997, 3:797-801.
• [7]Molberg O, McAdam SN, Sollid LM: Role of tissue transglutaminase in celiac disease. J Pediatr Gastroenterol Nutr 2000, 30:232-240.
• [8]Zanoni G, Navone R, Lunardi C, Tridente G, Bason C, Sivori S, Beri R, Dolcino M, Valletta E, Corrocher R, Puccetti A: In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med 2006, 3:e358.
• [9]Barone MV, Caputo I, Ribecco MT, Maglio M, Marzari R, Sblattero D, Troncone R, Auricchio S, Esposito C: Humoral immune response to tissue transglutaminase is related to epithelial cell proliferation in celiac disease. Gastroenterology 2007, 132:1245-1253.
• [10]Teesalu K, Panarina M, Uibo O, Uibo R, Utt M: Autoantibodies from patients with celiac disease inhibit transglutaminase 2 binding to heparin/heparan sulfate and interfere with intestinal epithelial cell adhesion. Amino Acids 2012, 42:1055-1064.
• [11]Myrsky E, Kaukinen K, Syrjanen M, Korponay-Szabo IR, Maki M, Lindfors K: Coeliac disease-specific autoantibodies targeted against transglutaminase 2 disturb angiogenesis. Clin Exp Immunol 2008, 152:111-119.
• [12]Myrsky E, Caja S, Simon-Vecsei Z, Korponay-Szabo IR, Nadalutti C, Collighan R, Mongeot A, Griffin M, Maki M, Kaukinen K, Lindfors K: Celiac disease IgA modulates vascular permeability in vitro through the activity of transglutaminase 2 and RhoA. CMLS 2009, 66:3375-3385.
• [13]Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, Raulet DH, Lanier LL, Groh V, Spies T, Ebert EC, Green PH, Jabri B: Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004, 21:357-366.
• [14]Bahram S, Bresnahan M, Geraghty DE, Spies T: A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1994, 91:6259-6263.
• [15]Lopez-Larrea C, Suarez-Alvarez B, Lopez-Soto A, Lopez-Vazquez A, Gonzalez S: The NKG2D receptor: sensing stressed cells. Trends Mol Med 2008, 14:179-189.
• [16]Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T: Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001, 2:255-260.
• [17]Hue S, Mention JJ, Monteiro RC, Zhang S, Cellier C, Schmitz J, Verkarre V, Fodil N, Bahram S, Cerf-Bensussan N, Caillat-Zucman S: A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004, 21:367-377.
• [18]Dai Z, Turtle CJ, Booth GC, Riddell SR, Gooley TA, Stevens AM, Spies T, Groh V: Normally occurring NKG2D + CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J Exp Med 2009, 206:793-805.
• [19]Zou Y, Heinemann FM, Grosse-Wilde H, Sireci G, Wang Z, Lavingia B, Stastny P: Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol 2006, 67:230-237.
• [20]Zou Y, Stastny P, Susal C, Dohler B, Opelz G: Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007, 357:1293-1300.
• [21]Terasaki PI, Ozawa M, Castro R: Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007, 7:408-415.
• [22]Suarez-Alvarez B, Lopez-Vazquez A, Gonzalez MZ, Fdez-Morera JL, Diaz-Molina B, Blanco-Gelaz MA, Pascual D, Martinez-Borra J, Muro M, Alvarez-Lopez MR, Lopez-Larrea C: The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection. Am J Transplant 2007, 7:1842-1848.
• [23]Suarez-Alvarez B, Lopez-Vazquez A, Diaz-Pena R, Diaz-Molina B, Blanco-Garcia RM, Alvarez-Lopez MR, Lopez-Larrea C: Post-transplant soluble MICA and MICA antibodies predict subsequent heart graft outcome. Trans Immunol 2006, 17:43-46.
• [24]Cosnes J, Cellier C, Viola S, Colombel JF, Michaud L, Sarles J, Hugot JP, Ginies JL, Dabadie A, Mouterde O, Allez M, Nion-Larmurier I: Incidence of autoimmune diseases in celiac disease: protective effect of the gluten-free diet. Clin Gastroenterol Hepatol 2008, 6:753-758.
• [25]McNeish AS, Harms HK, Rey J, Shmerling DH, Visakorpi JK, Walker-Smith JA: The diagnosis of coeliac disease. A commentary on the current practices of members of the European Society for Paediatric Gastroenterology and Nutrition (ESPGAN). Arch Dis Child 1979, 54:783-786.
• [26]Husby S, Koletzko S, Korponay-Szabo IR, Mearin ML, Phillips A, Shamir R, Troncone R, Giersiepen K, Branski D, Catassi C, Lelgeman M, Maki M, Ribes-Koninckx C, Ventura A, Zimmer KP: European society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012, 54:136-160.
• [27]Bai JC, Fried M, Corazza GR, Schuppan D, Farthing M, Catassi C, Greco L, Cohen H, Ciacci C, Eliakim R, Fasano A, Gonzalez A, Krabshuis JH, LeMair A: World gastroenterology organisation global guidelines on celiac disease. J Clin Gastroenterol 2013, 47:121-126.
• [28]Bai JC, Fried M, Corazza GR, Schuppan D, Farthing M, Catassi C, Greco L, Cohen H, Ciacci C, Fasano A, Gonzalez A, Krabshuis JH, LeMair A: Celiac Disease. WGO Global Guidelines. 2012. http://www.worldgastroenterology.org/assets/export/userfiles/2012_Celiac%20Disease_long_FINAL.pdf webcite)
• [29]Lopez-Vazquez A, Rodrigo L, Fuentes D, Riestra S, Bousono C, Garcia-Fernandez S, Martinez-Borra J, Gonzalez S, Lopez-Larrea C: MICA-A5.1 allele is associated with atypical forms of celiac disease in HLA-DQ2-negative patients. Immunogenetics 2002, 53:989-991.
• [30]Lopez-Vazquez A, Rodrigo L, Fuentes D, Riestra S, Bousono C, Garcia-Fernandez S, Martinez-Borra J, Gonzalez S, Lopez-Larrea C: MHC class I chain related gene A (MICA) modulates the development of coeliac disease in patients with the high risk heterodimer DQA1*0501/DQB1*0201. Gut 2002, 50:336-340.
• [31]Tinto N, Ciacci C, Calcagno G, Gennarelli D, Spampanato A, Farinaro E, Tortora R, Sacchetti L: Increased prevalence of celiac disease without gastrointestinal symptoms in adults MICA 5.1 homozygous subjects from the Campania area. Digest Liver Dis 2008, 40:248-252.
• [32]Salardi S, Volta U, Zucchini S, Fiorini E, Maltoni G, Vaira B, Cicognani A: Prevalence of celiac disease in children with type 1 diabetes mellitus increased in the mid-1990s: an 18-year longitudinal study based on anti-endomysial antibodies. J Pediatr Gastroenterol Nutr 2008, 46:612-614.
• [33]Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, Bluestone JA, Lanier LL: NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 2004, 20:757-767.
• [34]Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T: Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA 2003, 100:9452-9457.
• [35]Martin-Pagola A, Ortiz L, Perez de Nanclares G, Vitoria JC, Castano L, Bilbao JR: Analysis of the expression of MICA in small intestinal mucosa of patients with celiac disease. J Clin Immunol 2003, 23:498-503.
• [36]Perera L, Shao L, Patel A, Evans K, Meresse B, Blumberg R, Geraghty D, Groh V, Spies T, Jabri B, Mayer L: Expression of nonclassical class I molecules by intestinal epithelial cells. Inflamm Bowel Dis 2007, 13:298-307.
• [37]Lopez-Vazquez ARL, Gonzalez S, Lopez-Larrea C: NKG2D ligands expression patterns in gut mucosa from patients with coeliac disease. Inmunologia 2013, 32:43-49.
• [38]Makhlouf L, Kishimoto K, Smith RN, Abdi R, Koulmanda M, Winn HJ, Auchincloss H Jr, Sayegh MH: The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade. Diabetes 2002, 51:3202-3210.
• [39]Ventura A, Magazzu G, Greco L: Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease. Gastroenterol 1999, 117:297-303.
• [40]Sategna Guidetti C, Solerio E, Scaglione N, Aimo G, Mengozzi G: Duration of gluten exposure in adult coeliac disease does not correlate with the risk for autoimmune disorders. Gut 2001, 49:502-505.